Inhalon Biopharma is a clinical-stage biotechnology company developing faster-acting, more effective, self-administered inhaled treatments to address the over $40B worldwide unmet need for patients suffering from acute respiratory infections (ARIs), including respiratory syncytial virus (RSV), influenza, HMPV and SARS-CoV-2. Inhalon is using its patented drug delivery platform to revolutionize the treatment of viral respiratory infections. Inhalon’s breakthrough is a muco-trapping technology that directly binds to the virus and physically clears it. Virus trapping results in immediate reduction of viral load and prevents severe infection. Inhalon is the only company with broad issued patents covering inhaled treatment of ARIs with human monoclonal antibodies. Already, current partnerships with USAMRDC, NIH and Celltrion Healthcare have provided validation and funding to advance Inhalon’s proprietary platform.